|
1
|
Inoue M, Yoshimi I, Sobue T and Tsugane S:
JPHC Study Group. Influence of coffee drinking on subsequent risk
of hepatocellular carcinoma: A prospective study in Japan. J Natl
Cancer Inst. 97:293–300. 2005.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kashino I, Akter S, Mizoue T, Sawada N,
Kotemori A, Matsuo K, Oze I, Ito H, Naito M, Nakayama T, et al:
Coffee drinking and colorectal cancer and its subsites: A pooled
analysis of 8 cohort studies in Japan. Int J Cancer. 143:307–316.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Emile SH, Barsom SH, Garoufalia Z and
Wexner SD: Does drinking coffee reduce the risk of colorectal
cancer? A qualitative umbrella review of systematic reviews. Tech
Coloproctol. 27:961–968. 2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Alicandro G, Tavani A and La Vecchia C:
Coffee and cancer risk: A summary overview. Eur J Cancer Prev.
26:424–432. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Miura Y, Furuse T and Yagasaki K:
Inhibitory effect of serum from rats administered with coffee on
the proliferation and invasion of rat ascites hepatoma cells.
Cytotechnology. 25:221–225. 1997.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Miura Y, Ono K, Okauchi R and Yagasaki K:
Inhibitory effect of coffee on hepatoma proliferation and invasion
in culture and on tumor growth, metastasis and abnormal lipoprotein
profiles in hepatoma-bearing rats. J Nutr Sci Vitaminol (Tokyo).
50:38–44. 2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Villota H, Santa-González GA, Uribe D,
Henao IC, Arroyave-Ospina JC, Barrera-Causil CJ and Pedroza-Díaz J:
Modulatory effect of chlorogenic acid and coffee extracts on
Wnt/β-catenin pathway in colorectal cancer cells. Nutrients.
14(4880)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vélez-Vargas LC, Santa-González GA, Uribe
D, Henao-Castañeda IC and Pedroza-Díaz J: In vitro and in silico
study on the impact of chlorogenic acid in colorectal cancer cells:
Proliferation, apoptosis, and interaction with β-catenin and LRP6.
Pharmaceuticals (Basel). 16(276)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Murai T and Matsuda S: The chemopreventive
effects of chlorogenic acids, phenolic compounds in coffee, against
inflammation, cancer, and neurological diseases. Molecules.
28(2381)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gupta A, Atanasov AG, Li Y, Kumar N and
Bishayee A: Chlorogenic acid for cancer prevention and therapy:
Current status on efficacy and mechanisms of action. Pharmacol Res.
186(106505)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Francisco LM, Sage PT and Sharpe AH: The
PD-1 pathway in tolerance and autoimmunity. Immunol Rev.
236:219–242. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Fife BT and Bluestone JA: Control of
peripheral T-cell tolerance and autoimmunity via the CTLA-4 and
PD-1 pathways. Immunol Rev. 224:166–182. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gianchecchi E, Delfino DV and Fierabracci
A: Recent insights into the role of the PD-1/PD-L1 pathway in
immunological tolerance and autoimmunity. Autoimmun Rev.
12:1091–1100. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Okazaki T and Honjo T: PD-1 and PD-1
ligands: From discovery to clinical application. Int Immunol.
19:813–824. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Homet Moreno B and Ribas A:
Anti-programmed cell death protein-1/ligand-1 therapy in different
cancers. Br J Cancer. 112:1421–1427. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Sadreddini S, Baradaran B, Aghebati-Maleki
A, Sadreddini S, Shanehbandi D, Fotouhi A and Aghebati-Maleki L:
Immune checkpoint blockade opens a new way to cancer immunotherapy.
J Cell Physiol. 234:8541–8549. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319.
2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chang E, Pelosof L, Lemery S, Gong Y,
Goldberg KB, Farrell AT, Keegan P, Veeraraghavan J, Wei G,
Blumenthal GM, et al: Systematic review of PD-1/PD-L1 inhibitors in
oncology: From personalized medicine to public health. Oncologist.
26:e1786–e1799. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Twomey JD and Zhang B: Cancer
Immunotherapy update: FDA-approved checkpoint inhibitors and
companion diagnostics. AAPS J. 23(39)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang Q, Yang C, Gao X, Dong J and Zhong
C: Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint
blockade therapy. Phytother Res. 38:776–796. 2024.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Peng M, Fan S, Li J, Zhou X, Liao Q, Tang
F and Liu W: Programmed death-ligand 1 signaling and expression are
reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in
tongue squamous cell carcinoma. Genes Nutr. 17(3)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Li L, Zhang M, Liu T, Li J, Sun S, Chen J,
Liu Z, Zhang Z and Zhang L: Quercetin-ferrum nanoparticles enhance
photothermal therapy by modulating the tumor immunosuppressive
microenvironment. Acta Biomater. 154:454–466. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Jing D, Wu W, Chen X, Xiao H, Zhang Z,
Chen F, Zhang Z, Liu J, Shao Z and Pu F: Quercetin encapsulated in
folic acid-modified liposomes is therapeutic against osteosarcoma
by non-covalent binding to the JH2 domain of JAK2 via the
JAK2-STAT3-PDL1. Pharmacol Res. 182(106287)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jiang ZB, Wang WJ, Xu C, Xie YJ, Wang XR,
Zhang YZ, Huang JM, Huang M, Xie C, Liu P, et al: Luteolin and its
derivative apigenin suppress the inducible PD-L1 expression to
improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer
Lett. 515:36–48. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Coombs MRP, Harrison ME and Hoskin DW:
Apigenin inhibits the inducible expression of programmed death
ligand 1 by human and mouse mammary carcinoma cells. Cancer Lett.
380:424–433. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Dimitrov V, Bouttier M, Boukhaled G,
Salehi-Tabar R, Avramescu RG, Memari B, Hasaj B, Lukacs GL,
Krawczyk CM and White JH: Hormonal vitamin D up-regulates
tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in
humans but not mice. J Biol Chem. 292:20657–20668. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yagasaki K, Miura Y, Okauchi R and Furuse
T: Inhibitory effects of chlorogenic acid and its related compounds
on the invasion of hepatoma cells in culture. Cytotechnology.
33:229–235. 2000.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sarkaria JN, Busby EC, Tibbetts RS, Roos
P, Taya Y, Karnitz LM and Abraham RT: Inhibition of ATM and ATR
kinase activities by the radiosensitizing agent, caffeine. Cancer
Res. 59:4375–4382. 1999.PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yoshida T, Yamasaki K, Tadagaki K,
Kuwahara Y, Matsumoto A, Sofovic AE, Kondo N, Sakai T and Okuda T:
Tumor necrosis factor-related apoptosis-inducing ligand is a novel
transcriptional target of runt-related transcription factor 1. Int
J Oncol. 60(6)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Dranoff JA: Coffee, adenosine, and the
liver. Purinergic Signal. 20:21–28. 2024.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Song X, Kirtipal N, Lee S, Malý P and
Bharadwaj S: Current therapeutic targets and multifaceted
physiological impacts of caffeine. Phytother Res. 37:5558–5598.
2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Montoya GA, Bakuradze T, Eirich M, Erk T,
Baum M, Habermeyer M, Eisenbrand G and Richling E: Modulation of
3',5'-cyclic AMP homeostasis in human platelets by coffee and
individual coffee constituents. Br J Nutr. 112:1427–1437.
2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dixon R, Hwang S, Britton F, Sanders K and
Ward S: Inhibitory effect of caffeine on pacemaker activity in the
oviduct is mediated by cAMP-regulated conductances. Br J Pharmacol.
163:745–754. 2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sasi B, Ethiraj P, Myers J, Lin AP, Jiang
S, Qiu Z, Holder KN and Aguiar RCT: Regulation of PD-L1 expression
is a novel facet of cyclic-AMP-mediated immunosuppression.
Leukemia. 35:1990–2001. 2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ugai T, Matsuo K, Sawada N, Iwasaki M,
Yamaji T, Shimazu T, Goto A, Inoue M, Kanda Y, Tsugane S, et al:
Coffee and green tea consumption and subsequent risk of acute
myeloid leukemia and myelodysplastic syndromes in Japan. Int J
Cancer. 142:1130–1138. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Slominski RM, Raman C, Chen JY and
Slominski AT: How cancer hijacks the body's homeostasis through the
neuroendocrine system. Trends Neurosci. 46:263–275. 2023.PubMed/NCBI View Article : Google Scholar
|
